Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients

Completed

• Conditions: Compliance; Gastroprotector Therapy; Risk Factors

• Registration Number: NCT00699725
• Lead Sponsor: AstraZeneca

Brief Summary

Prospective multicentric study to evaluate the compliance of gastroprotective treatment in NSAID patients at risk of GI complications. Secondary objectives: To identify the factors associated to treatment compliance (both NSAID and PPI), to evaluate the relationship between compliance and NSAID-associated GI events

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05
• Study First Submitted: 2008-06-17
• Study First Submitted QC: 2008-06-17
• Study First Posted: 2008-06-18
• Primary Completion: 2009-01
• Study Completion: 2009-01
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-06
• Last Update Posted: 2010-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Signed informed consent
• Patients consulting to the specialized care clinics who have been prescribed NSAID and gastroprotection for at least 15 days following standard clinical practice.

Read More

Exclusion Criteria

• Any gastroprotective treatment prescribed for other condition than NSAID-related gastrointestinal event prevention

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adherence to gastroprotection treatment	End of follow-up (3-5 weeks)

Secondary Outcome Measures

Name	Time	Method
Identify factors associated with treatment compliance	End of follow-up
Evaluate the relationship among GI events and treatment compliance	End of follow-up

Trial Locations

Locations (1)

Research Site; 🇪🇸 Zaragoza, Spain